**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2016-2017/262

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | FINAGEN 5 TABLETS | | **REF. NO: NDQD201509261** |
| **DATE RECEIVED:** 08.09.2015 | **LABEL CLAIM:** | Each film - coated tablet contains: Finasteride Ph. Eur. 5 mg. | |
| **BATCH NO.:** FN0514241-A | **PRESENTATION:** | Sky blue coloured, circular shaped, biconvex faced tablets, embossed '61' on one face and 'E' on the other , packed in a blister strip of 10 tablets and 2 such strips in a printed box. | |
| **MFG. DATE:** Oct.2014 | **MANUFACTURER:** | AUROBINDO Pharma Ltd. | |
| **EXP. DATE:**  Sep.2016 | **ADDRESS:** | Unit 111, Survey No. 313, Bachupally Village, Quthubullapur Mandal, Ranga Reddy District (A.P.)., INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | Simba Pharmaceuticals Limited P. O. Box 1541 - 00606, Nairobi, KENYA | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App. XII C | NMT 2 tablets deviate by more than 7.5% from mean tablet weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Manufacturer's In-House Method | RT of the major peak in the assay sample preparation corresponds to that in the assay standard preparation | Super-imposable peak at RT; 5.8 -/+ 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Manufacturer's In-House Method | No tablet less than 80% | Average | **COMPLIES** |
| **Dissolution** |  |  |  | 98% Range |  |
| **Dissolution** |  |  |  | 96 - 99% (RSD=1.2%; n=6) |  |
| **Assay** | HPLC | Manufacturer's In-House Method | 95.0 - 105.0% | 96.4% (RSD=0.7%; n=9) | **COMPLIES** |

**CONCLUSION:** The sample complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| **NULL** | NULL | .......................................................... | DATE: null |
| **DIRECTOR:** | HEZEKIAH CHEPKWONY | .......................................................... | DATE: 11-18-2016 |